LTR Pharma (ASX:LTP) Debt-to-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Debt-to-Asset?

LTR Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was A$0.00 Mil. LTR Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was A$0.00 Mil. LTR Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was A$7.51 Mil. LTR Pharma's debt to asset for the quarter that ended in Jun. 2023 was 0.00.

LTR Pharma Debt-to-Asset Historical Data

The historical data trend for LTR Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Debt-to-Asset Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-Asset

0.85

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Debt-to-Asset	0.85	-	-

Competitive Comparison of LTR Pharma's Debt-to-Asset

For the Biotechnology subindustry, LTR Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Debt-to-Asset falls into.

LTR Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

LTR Pharma's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.51
	=	0.00

LTR Pharma's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.51
	=	0.00

LTR Pharma (ASX:LTP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

LTR Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines